Use of Desferal for Prevention of ARDS in Hospitalised Cases Documented With Covid 19 Infection

• Status: Not yet recruiting
• Trial end date: 2020-12-31
• Target enrollment: 0
• Participant gender: All

Summary

To evaluate the efficacy of using Desferal injections for prevention of ARDS in moderate cases with fever , chest tightness and relevant chest images

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Hesham Al-Inany
• Treatments: Deferoxamine

Criteria

Inclusion Criteria:

• Patients positive for Covid 19 admitted to hospital with chest tightness

Exclusion Criteria:

• Pregnancy

• Breastfeeding

• Known severe hepatic impairment

• Known severe renal impairment

• Known porphyrias

• Diabetes mellitus

• Known G6PD deficiency

• Known myasthenia gravis

• Known severe psoriasis

• Known severe neurological disorders (especially those with a history of epilepsy - may lower seizure threshold)